HomeEurofins Transplant Genomics

Eurofins Transplant Genomics

Labs@Home™ Facilitates Outpatient Management of Kidney Transplants During COVID-19

TruGraf, the only blood test approved by CMS for surveillance to rule out "silent" subclinical acute rejection (subAR) in kidney transplant recipients with stable graft function, has been recognized as crucial to reducing risk in outpatient management after a kidney transplant during COVID-19 in a recently published article from Yale University.

Eurofins – Transplant Genomics Announces TRULO Registry Study to Evaluate Long-Term Clinical Outcomes in Patients Monitored with TruGraf® Testing

TRULO is a prospective, multicenter observational registry study, designed to evaluate post-transplant clinical outcomes in recipients of kidney transplants who are undergoing serial TruGraf testing.